Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on In Vitro Hepatic Lipogenesis-Related Gene Expression

Table 2

Demographic characteristics, comorbidities, and medication in patients with and without gout.

Variable	Gout		value
	No	Yes
	Sex	(%)		(%)	0.99
Female	39952 (22.5)	9988 (22.5)
Male	137700 (77.5)	34425 (77.5)
Age, mean (SD)^#	47.3 (17.1)	47.9 (16.9)	<0.001
Stratified age			0.99
≤49	102312 (57.6)	25578 (57.6)
50-64	42884 (24.1)	10721 (24.1)
65+	32456 (18.3)	8114 (18.3)
Comorbidity
Hypertension	19455 (11.0)	6396 (14.4)	<0.001
Stroke	6654 (3.75)	2063 (4.65)	<0.001
Diabetes	4786 (2.69)	1674 (3.77)	<0.001
COPD	8137 (4.58)	2507 (5.64)	<0.001
CAD	7870 (4.43)	2839 (6.39)	<0.001
Alcohol-related illness	7922 (4.46)	2728 (6.14)	<0.001
Asthma	5049 (2.84)	1723 (3.88)	<0.001
Medication
Allopurinol		6346 (14.3)
Febuxostat		93 (0.21)
Benzbromarone		19286 (43.4)
Sulfinpyrazone		1275 (2.87)
Probenecid		226 (0.51)
Colchicine		22482 (50.6)

Chi-square test. ^#Student’s -test.